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Traditionally, biomedical research endeavors in low to middle resources countries have focused on communicable
diseases. However, data collected over the past 20 years by the World Health Organization (WHO) show a
significant increase in the number of people suffering from non-communicable diseases (e.g. heart disease,
diabetes, cancer and pulmonary diseases). Within the coming years, WHO predicts significant decreases in
communicable diseases while non-communicable diseases are expected to double in low and middle income
countries in sub-Saharan Africa. The predicted increase in the non-communicable diseases population could be
economically burdensome for the basic healthcare infrastructure of countries that lack resources to address this
emerging disease burden. Biomedical research could stimulate development of healthcare and biomedical
infrastructure. If this development is sustainable, it provides an opportunity to alleviate the burden of both
communicable and non-communicable diseases through diagnosis, prevention and treatment. In this paper, we
discuss how research using biomedical technology, especially genomics, has produced data that enhances the
understanding and treatment of both communicable and non-communicable diseases in sub-Saharan Africa. We
further discuss how scientific development can provide opportunities to pursue research areas responsive to the
African populations. We limit our discussion to biomedical research in the areas of genomics due to its substantial
impact on the scientific community in recent years however, we also recognize that targeted investments in other
scientific disciplines could also foster further development in African countries.
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Advances in medicine using recent biomedical technolo-
gies, novel chemotherapeutic interventions and treat-
ment regimens has allowed for rapid diagnosis and
treatment of diseases, thus prolonging life for a signifi-
cant number of people [1,2]. This is demonstrated by the
substantial increase in the global life expectancy at birth
in the past 20 years. Globally, male and female life ex-
pectancy has increased from 56.4 yrs and 61.2 yrs re-
spectively to 67.5 yrs and 73.3 yrs in the decade from
1990 to 2010 [3]. In sub-Saharan Africa (SSA), substantial
reductions in childhood mortality, through the introduc-
tion of life saving antiretroviral therapy and other pre-
ventative measures against communicable diseases are
credited with the observed increases in life expectancy* Correspondence: peprahek@mail.nih.gov
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distribution, and reproduction in any medium[3]. Whereas global life expectancy is the standard metric
to measure the progress of countries toward combating
disease resulting in prolonged life, another statistic, the
healthy life expectancy (HALE) summarizes mortality
and non-fatal outcomes of disease (e.g. longevity) in a
single measure of averaged population health [4].
In 1990, countries with the lowest HALE for both
sexes were in SSA except for Afghanistan [4]. Similar to
life expectancy, HALE for a person at age 50 improved
in the past 20 years (i.e. 1990 to 2010) for most coun-
tries, including many in SSA [4]. As increases in life
expectancy occurred, years lived with disability (YLD)
remained largely unchanged over the same 20-year
period [5]. Life expectancy, HALE and YLD demonstrate
that success has been mixed because: 1) as life expect-
ancy has increased globally, countries in SSA are at the
bottom of this and other measures and 2) the majority
of diseases which have caused YLDs to remain relatively
unchanged are non-communicable diseases (NCDs) andCentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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for individuals have improved and increased the lifespan
of many living with HIV/AIDS) [5].
With the observed increase in life expectancy, one
could properly ask: Have genomic technologies contrib-
uted to this increase globally? If biomedical technologies,
especially genomics have contributed to the increase in
global life expectancy this would be one major justifica-
tion for increased investment of these technologies in
SSA. Although communicable diseases have decreased
in SSA, the major challenges for the next few decades
will include health issues associated with NCDs. Signifi-
cant increases in YLDs for people living in SSA with well
managed chronic conditions due to NCDs and infectious
diseases will also become a challenge [5]. Biomedical sci-
ence can play a role in combating the rise in NCDs and
chronic conditions. For instance, biomedical science has
the potential to improve the quality of life for many by
identifying the optimal treatment regimens for several
conditions [6-8]. Furthermore, the application of bio-
medical research to solve vexing problems has led to the
creation of new fields of scientific inquiry and expansion
of other areas spurring innovation [9,10]. In fact, publi-
cation of the human genome sequence has revolution-
ized medicine allowing the characterization of novel
disease-related genetic variants. In this capacity, genom-
ics (i.e. elucidating disease states by using technologies
that characterize human and also non-human genomes)
can be a very useful tool to further address communic-
able and non-communicable diseases in SSA because in-
vestments in biotechnology, especially genomics, have
significantly impacted other regions. Although invest-
ments in genomic technologies have increased in other
regions of the world, scientists in low- to middle-income
countries that could utilize these technologies to im-
prove health and to promote equity are concerned that
the commercial development of genomic technologies
will widen the gap between the developed and the devel-
oping world [11]. This concern was recognized by the
World Health Organization (WHO) over a decade ago;
the WHO commissioned the report Genomics and
World Health in recognition of the potential and signifi-
cant positive and negative impacts genomics could have
on global health [12]. A decade after the WHO report
was published, large-scale investments in biotechnology
and human genomic studies have been made by Mexico,
India, China and Thailand producing both economic
and scientific dividends which we suggest have had a
beneficial effect on life expectancy [2,13-15]. Within
these countries an increase in life expectancy has been
observed which can be attributed to medical innovation
sparked by biotechnology and genomics (large scale vac-
cination programs), non-medical programs (continued
education, improved literacy rate of the population) andother factors [16]. The factors necessary for the develop-
ment and sustained utilization of large scale biotechnology
including genomics, to develop sustainable economies are
thoroughly discussed by Singer, Daar and colleagues
[2,13,17,18]. This paper will express similar themes and
focus on how biomedical research can address communic-
able and non-communicable diseases in Africa.
Communicable diseases
Globally, deaths from communicable diseases, and mater-
nal, neonatal and nutritional causes decreased by ~ 2.7
million from 1990 to 2010 (from 15.9 million deaths to
13.2 million deaths respectively) [19]. Notwithstanding,
this observed decrease in deaths from communicable dis-
eases, Southeast Asia and Africa together bore 54% of the
total global burden of disease while accounting for only
40% of the world’s population [20]. With the significant
decrease in deaths from communicable diseases, SSA still
accounts for a significant burden of communicable disease
worldwide [20]. Interestingly, the decrease in deaths from
communicable, maternal, neonatal, and nutritional causes
was due to significant reductions in several diseases (i.e.
diarrheal diseases, lower respiratory infections, neonatal
disorders, measles and tetanus) which reflect scaling up
of effective treatments and utilization of technologies to
combat these disorders associated with poverty [19].
Other communicable diseases including HIV/AIDS and
malaria, contributed to a massive increase in deaths from
1990 to 2010; however, this increase did not affect the
overall decrease observed from aggressive scaling up of
medical interventions for children (0–12 yrs), which
were the major age group that died from communicable
diseases [19]. The significant reduction in child deaths
associated with communicable diseases has increased
universal life expectancy.
Biomedical and genomic technologies have been used
to derive host-parasite relationships (e.g. between human-
parasite, parasite-vector, and human-vector interactions)
that have significantly increased our understanding of these
complex interactions [21,22]. Traditionally, fieldwork
has occurred in SSA to sample zoonotic vectors, para-
sites and infected humans in the areas where outbreaks
have occurred. Fieldwork has allowed sample collection
resulting in the genomes of Plasmodium falciparum
[23], Trypansoma brucei [24], Leishmania major [25],
and Schistosoma mansoni [26] being sequenced with add-
itional molecular, biochemical and bioinformatics analyses
[27]. For instance, data acquired from those scientific
endeavors have been used to develop new therapies for
schistosomiasis [28], trypanosomiasis [29] and malaria
[30], using both genomics and traditional approaches,
which have decreased the burden of disease in SSA. Cur-
rently, researchers are testing combinations of malaria
treatments to find regimens suitable for children and also
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[6]. Another technology, the genome-wide associations
study (GWAS), has been used to provide genetic candi-
dates for the development of control measures against mal-
aria [6,31]. Samples collected during outbreaks have
yielded new discoveries about both the infectious agents
and population susceptibilities. Moreover, systematic
analysis of samples collected during outbreaks (e.g. large
vector and parasite collections) has allowed for determin-
ation of parasite susceptibility using pharmacological
compounds [32]. In the future, investigation of genetic
diversity of both vector and parasites within the environ-
ment using genomics will shed light on the distribution,
epidemiological importance and evolutionary history of
malaria vectors in the African rainforest [33]. Many of
these new efforts, in which genomic technologies were uti-
lized to investigate malaria and other infectious diseases,
are being led by African investigators in Africa and they
include chemotherapeutic interventions [6,33-35]. Publi-
cations highlight the emerging evidence that African sci-
entists, with support from local and international partners,
are starting to set a research agenda for the continent. The
aforementioned examples showcased in various publica-
tions include: 1) improved diagnosis, 2) scaling up of treat-
ment, 3) elucidation of the development of drug resistance
in unicellular organisms, 4) elucidation of human genetic
variants that affect drug metabolism, and 5) development
of genomic tools for population-level analysis of parasite
and human [14,36]. In the field of infectious disease, appli-
cation of genomics technologies has been instrumental in
the elucidation of the complex biology of infectious agents
and how they interact with hosts [37].
In addition to malaria, African scientists have used
genomic technologies (such as GWAS) to characterize
HIV/AIDS in SSA, which has gained significant atten-
tion from researchers inside and outside SSA [7,38].Table 1 GWAS of African and African ancestry populations on
Human Genome Research Institute catalogue of published ge
Disease Sample size Replicatio
HIV (mother-to-child transmission) 100 Malawian infant cases,
126 Malawian infant controls
NR
HIV-1 susceptibility 848 Malawian cases,
531 Malawian controls
NR
HIV-1 viral setpoint 496 HIV-1 infected individuals
of African ancestry; 302 HIV-1
exposed and uninfected
individuals of African ancestry
NR
Malaria 958 Gambian cases; 1,382
Gambian controls; all children
1,087 Gam
controls, a








NR not replicated, NS not significant.Genomic analysis of both African and non-African popu-
lations have found that several genetic variants (e.g. che-
mokine receptors, HLA, mannose-binding receptor and
other genes) can provide increased resistance or suscepti-
bility to HIV infections (Table 1) [7]. Africa could offer
more research opportunities on HIV explicating the roles
of these variants in HIV infections to improve prevention,
care, and treatment prospects for individuals at risk of the
disease [39]. Table 1 provides examples of GWAS and
other studies pertaining to HIV, malaria, and tuberculosis
which used mostly African and African ancestry pop-
ulations (e.g. African Americans in the United States).
Population-based genomic analyses has produced data
about genetic susceptibility to disease and illuminated
population-specific preventive approaches that could de-
crease HIV infections. Similar to the emergence of African
investigators in the field of parasitology, many investigators
on the African continent continue to elucidate HIV biol-
ogy, treatment, transmission and also the effects of HIV on
culture, social stigma and other negative societal issues of
the disease [40-42].
We highlight genomics- and biotechnology-related re-
search that was used to characterize and comprehend
communicable diseases and demonstrate that this re-
search has also led the way for substantial advances and
improvements in the health of populations in SSA. Many
countries (e.g. India, Brazil and China) have addressed
communicable diseases by developing robust biotech-
nology industries [47,48]. Development of biotechnology
(e.g. genomic research, and biopharmaceuticals) allows
countries to benefit economically by lowering the cost of
health-related products for local populations [48]. Globally,
development of biotechnology has been a factor in increas-
ing health and life expectancy in SSA, so we argue that a
substantial investment in this area will produce significant
benefit for SSA. We suggest that a similar model focusedcommunicable diseases obtained from the National
nome-wide association studies (GWAS)
n sample size Genes Ref
NS [43]
AL591509.5, GLRX3, TXNL3, FAM174B,
AC009271.7, ZDHHC19, BUD13
[44]
VEGFC, EPHA5, HIST1H4A, AL391500.13,
KB-67B5.12, CMTM8, AC095058.3,
AC087190.5-2, DNAJC5B, ZFP90, MAD2L1,
HSP90AB3P, Intergenic chr 2, GALNT14
[45]
bian cases; 2,376 Gambian
ll children
HBB, SCO1, DDC [31]
aian cases; 3,825 Ghanaian
36 Malawian cases; 779
controls; 332 Ghana
ld trios and duos
GATA6,CTAGE1,RBBP8,CABLES1 [46]
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creases in NCDs as reported by the Global Burden of Dis-
ease 2010 report [37,49,50].
Non-communicable diseases
Communicable diseases account for the plurality of deaths
in many African countries; however, there is a need to in-
crease biomedical research in the areas of NCD. The bur-
den of NCDs (e.g. heart disease, diabetes, some cancers
and pulmonary disease) are expected to double in low-
and middle-income countries within the next few decades
[51]. The number of deaths from NCDs rose in 2010 by
almost 34.5 million globally as deaths caused by commu-
nicable diseases decreased [19]. It is predicted that the
healthcare systems of these countries will not be able to
support the treatment of NCDs (e.g. Sickle Cell Disease
(SCD)) especially in African countries in which the health
infrastructure is taxed by infectious diseases [51]. The
increase in chronic diseases would suggests that a re-
alignment of priorities is needed in which substantially
greater focus should be on mitigating the projected in-
creases in NCDs in SSA. We argue that genomic tech-
nologies can benefit African populations in the area of
non-communicable diseases by briefly discussing the
knowledge scientists have gained about NCDs using these
technologies.
GWAS and other genomic technologies have had con-
siderable influence on the identification of genetic vari-
ants associated with NCDs. Several GWAS on NCDsTable 2 GWAS on non-communicable diseases in African and
National Human Genome Research Institute catalogue of pub
Disease/Trait Sample size Re
Asthma 422 cases; 1,533 controls 3,
59
bl
Asthma 464 African American cases; 471
African American controls; 1,028





Asthma 793 European ancestry child cases;





Asthma 2,088 European American cases;
1,612 African American and African




Sickle cell anemia (severity) 177 African American severe patients;
1,088 African American mild patients
68
Sickle cell anemia (HbF modifiers) 2040 African American sickle cell
anemia patients
N




NR not replicated, NS not significant.have been conducted with African and African ancestry
populations. Asthma is a complex NCD that significantly
affects both the young and old [52]. In the countries
in which asthma has be explored, many have reported
that hospitalizations for asthma are 2–3 times higher for
African and African ancestry populations compared to
other ethnic groups [52,53]. GWAS exploring the genetic
basis of disease in African ancestry populations have iden-
tified several genes associated with asthma susceptibility
(Table 2). GWAS have found that different genetics vari-
ants were associated with asthma susceptibility in children
of European and African ancestry suggesting different bio-
logical mechanisms could be at the basis of asthma sus-
ceptibility in these diverse populations [54,55].
Unlike asthma, the primary genetic variant underlying
SCD has been identified, but the tools of GWAS are be-
ing used to determine the nature of the genetic modi-
fiers associated with phenotypic diversity in SCD. SCD is
the most common monogenic disease, occurring at its
highest frequency in SSA [61]. As an illustration, people
suffering from SCD will increasing effect public healthcare
systems in SSA; it is predicted that 312,000 neonates with
SCD are born globally with ~240,000 of those births being
in SSA [62]. The combined populations of births of hetero-
zygous and homozygous carriers of the SCD gene mutation
HbAS is estimated at ~3.6 million and for HbSS ~240,000,
respectively, producing an estimated ~4 million live births
per year with SCD gene mutation [62]. In this capacity,
SCD and other hemoglobinopathies represent a healthrecent African ancestry populations obtained from the
lished genome-wide association studies (GWAS)
plication sample size Genes Ref
750 white cases; 13,365 white controls;
2 white trios; 1,903 black cases; 2,432
ack controls; 929 black family members
PDE4D [55]
4 European descent cases; 1,243
ropean descent controls; 2,331 African
scent cases, 2,874 African descent
ntrols (includes family members)
NS [56]
7 European ancestry child cases;
546 European ancestry child controls;
667 African American child cases;
045 African American child controls
DENND1B, CRB1 [54]
727 European American cases; 2,147
rican American and African Caribbean
se; 2,299 Latino cases
GSDMB, IL1RL1, TSLP, IL33,
PYHIN1, C11orf71, CRCT1
[57]
severe patients; 95 mild patients NS [58]
R BCL11A, HBS1L-MYB [59]
2 family trios (two parents and one
fected child) for family-based association
sting; 94 cases and 94 controls for
LA-typing
HLA-DQA1 [60]
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SSA [63]. An example of effective application of genomic
technology for SCD in SSA could be the wide scale early
diagnosis and preventive treatment of SCD, along with
other hemoglobinopathies and monogenic disorders. The
burden of SCD is disproportionately located in Africa;
thus, prioritizing diagnosis, treatment and prevention for
the low- and middle-income countries would be an effect-
ive means of bridging the gap between these and high-
income countries. Furthermore, introduction of preventive
genetic methods such as the utilization of DNA tech-
nology in childhood disease screenings to identify causal
genetic variants would be beneficial to populations in
SSA and considered an appropriate point of entry for
genomic technologies [11]. An example that occurred in
SSA is a Cameroonian center that recently introduced
detection for SCD; this service offers reproductive op-
tions to families [64].
Moreover, genes implicated in SCD severity have been
shown to modulate fetal hemoglobin (HbF) levels and
were confirmed by GWAS in African and African ances-
try populations [65]. A study showed that the 3 loci de-
scribed in other populations that affect HbF levels and
clinical severity has a significant impact in Tanzanian pa-
tients [66]; however, some variants affecting HbF in
Tanzanians are not well represented in European popu-
lations. This and other similar findings suggest that there
is a need to search for additional loci through independ-
ent GWAS in African populations [66]. Identifying loci
that affect HbF levels and, consequently, disease severity
could be used to anticipate one’s ability to produce HbF
from birth, and plan in advance the introduction of
treatment (e.g. hydroxyurea, a drug which has been
shown to increase concentrations of HbF) to reduce the
negative impact of SCD, which could include pain crises,
acute chest syndrome and severe anemia resulting in blood
transfusions [67]. Interestingly, evidence supports asthma
and SCD as distinct co-morbid conditions in which the
underlying mechanisms of phenotypic variations of the
two diseases might be similar [68-70]. Table 2 lists GWAS
studies that have found associations for genetic variants in
NCDs. For both asthma and SCD, the complexity of the
phenotype would suggest that genetic heterogeneity is a
major contributor to the clinical severity in both diseases.
Furthermore, the diversity within African populations can
lead to a comprehensive characterization of genetic vari-
ants associated these both asthma and SCD.
Another NCD, Podoconiosis also called non-filarila
elephantiasis of the lower leg, occurs in SSA because of
environmental exposure to soil. Recently, family-based
association study using GWAS was conducted to elucidate
the genetic underpinnings of podoconiosis. This study, fo-
cused on continental African population groups, found
genetic susceptibility to podoconiosis [60]. In addition toidentifying genes associated with NCDs such as podo-
conisosis, GWAS has been used to identify treatment out-
comes based on genotypes for NCDs. Overall; genomics-
related biomedical research has given a better picture of
the genetic underpinnings and molecular biology of many
of these diseases which affect SSA populations.
The Global Burden of Disease 2010 reported substan-
tial increases in cardiovascular disease; ischaemic heart
disease, stroke and chronic obstructive pulmonary dis-
ease were among the leading causes of death globally
[19]. In SSA, many have recognized that cardiovascular
diseases are a significant contributor to mortality; for ex-
ample, in Kenya, acute myocardial infarctions are not
uncommon [71]. Tanzania has observed a significant in-
crease in the number of deaths for cardiovascular disease
(from 16% in 2003 to 24% in 2007) [72]. In hypertension,
genetic variants found in African ancestry populations are
associated with differential responses to antihypertensive
drugs (e.g. thiazide diuretics) commonly used to regulate
blood pressure [73]. These genetic variants offer ways to
distinguish good responders (patients that show improve-
ment on diuretics) from non- or poor-responders (patients
with a negative response to diuretic mediations for the
treatment of hypertension) which provide information on
how best to treat hypertensive patients. Because of this es-
calating dilemma faced by low- to middle-income coun-
tries in SSA, considerable resources will be needed to
address the observed and impending ballooning of NCDs
(e.g. hypertension and cardiovascular diseases) in the com-
ing decades [19,72].
The observed increases of NCDs for the past 20 years
(1990 to 2010) are due to factors that include demo-
graphic changes leading to a rise in the proportion of
people older than 60 years [4,19]. This continued increase
in life expectancy has not been homogeneous globally
among age groups [3]. The heterogeneous distribution of
life expectancy globally has resulted in an increase in
people living longer with chronic conditions in SSA [74].
The scale of the challenge posed by the combined and
growing burden of chronic infectious diseases and NCDs,
including genetic conditions, demands an extraordinary re-
sponse that few SSA countries currently provide. With the
increase in life expectancy due to positive treatment out-
comes and increased prevention of disease, SSA will in-
crease its populations of the chronically ill in the coming
decades. This situation is illustrated by WHO data indicat-
ing that life expectancy has risen; however, YLDs has
remained constant globally [5]. We suggest that biotech-
nology and genomics can be used to address many of the
issues associated with NCDs, similar to their use in infec-
tious disease research. Also, a gradual increase in resources
available to understand NCDs, while also addressing com-
municable diseases, is needed [75]. Essentially, we envision
a model in which, as the burden of infectious diseases
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search focused on NCDs.
Challenges for genomics research in Africa
The present state of genomic research in Africa is in its
infancy; nevertheless, substantial biomedical research con-
tinues to occur in the areas of agriculture, genetics, bio-
medical science and several other areas [17]. Excluding
South Africa, research funding amounts to < .5% of GPD
indicating that the majority of funding for scientific re-
search, training and infrastructural development occur
through support from high-income countries [76]. Many
have suggested that the influx of donor money to support
African research has had a negative impact in which rela-
tively wealthy nations (e.g. Nigeria and Angola) do not in-
vest in funding to support biomedical research [77-79].
However, it must be acknowledged that significant infra-
structure exists in Africa for biomedical research. The chal-
lenges that exist for genomics research in Africa include
improving infrastructure, and creating and maintaining
sustainable collaborations that are currently present on the
continent.
Infrastructure for various research centers has been
created with financial and technical investment from the
United Nations, world governments, and biotechnology
companies with business interests on the continent
[13,80]. Currently infrastructure exists in South Africa,
Egypt, Tunisia, Nigeria and Kenya [81]. These centers
have also made substantial investments in agricultural
science compared to other Africa countries and are in-
creasing their research capacity [81]. Recently, African
countries have started to realize the necessity of developing
a vibrant research infrastructure from local government in-
vestments [51]. To address the issue of local investment,
members of the African Union (AU) of countries have
agreed to steadily increase funding for research until it
reaches at least 1% of GDP within the next few years [76].
This is a significant development and it demonstrates that
AU partner nations understand the value of research as a
potential mechanism to: 1) decrease the burden of disease
that affects their populations, 2) create cheaper and “home
grown” alternatives to pharmacological agents that are usu-
ally purchased from high-income countries, 3) acknow-
ledge the economic benefits that investments in research
infrastructure can develop through home-grown compan-
ies, which in turn provide jobs to citizens who eventually
pay taxes [2]. Local investments have occurred in many
countries in the Southern Hemisphere allowing these
countries to improve their economies which could be sug-
gested as a way forward for SSA [2,15,18].
A second challenge for genomics research in Africa
concerns research priorities of African countries and
the high-income countries which fund and support re-
search. Research priorities between high-income countries(i.e. United Kingdom, USA) and low- to middle-income
African countries differ in many areas [81]. In addition to
the differences, because SSA countries have a significant
communicable disease burden, and disproportionately have
more individuals affected by YLDs, African led research
endeavors could significantly reduce the mortality asso-
ciated with those diseases [5,76,79]. The differences in
research priorities between African countries and high-
income countries is illustrated by the lack of attention to
diarrhoeal diseases (DD) and lower respiratory infections
(LRI), which cause significant mortality in children in SSA
[5]. In 2006, only 26 clinical trials occurred for DD and
LRI (20 for DD and 6 for LRI) compared to 205 for malaria
[81]. This suggests the need for further development of re-
sources for African scientists to develop their own research
priorities. Case studies in Cameroon and Tanzania illus-
trate the potential of genomic research in SCD and its ap-
plications in public health interventions. More studies to
characterize genomic variations that affect phenotypes of
SCD and their application in primary and secondary pre-
ventions, as well as prospective studies on genomic-based
therapeutic interventions, could allow Africa, where two-
thirds of SCD patients live, play a major global role in he-
moglobinopathies research. With a significant decrease in
communicable diseases observed in the past 20 years for
SSA, a monumental shift has begun, suggesting a realign-
ment of goals and priorities for the next few decades
[4,5,19]. This realignment of priorities will occur as SSA
considers how best to address the ageing population.
The third challenge is overcoming the scientific dias-
poras that have emerged between low- to middle-income
countries compared to high-income countries [50,82]. The
large migration of physicians, nurses, scientists and other
highly educated professionals to high-income countries
termed, “brain drain”, is of considerable significance to
economic development [82]. African countries are placed
in a disadvantaged position for technology development
because professional, highly educated cadres of people are
needed to develop, operate and maintain these tech-
nologies and lead scientific endeavors. This migration
was illustrated in a 2004 report which stated that the im-
port of highly qualified medical professionals from Ghana
saved ~ £103 million (~$200 million) in training costs for
the National Health Service in the United Kingdom [83].
From this observation, some have argued compensation
for the country of origin was needed to offset the loss of
this important and critical human capital [84]. Currently,
in many regions of Africa with stable economies, migra-
tion is due to low salary for professionals [49]. The migra-
tion problem is prevalent in medicine and other scientific
fields [85]. Several groups have suggested that brain drain
is one major cause of scientific diasporas between indus-
trialized and emerging nations [50]. Other groups suggest
that the lack of infrastructure, economic development and
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drain is a symptom of these problems [18]. To address
how these problems have arisen, it is important to exam-
ine the scientific diasporas in a new paradigm in which
engagement of the continent, with equal partnership in
developing collaborative research priorities which are also
associated with economic development is paramount [86].
This scientific diasporas can be overcome via several
mechanisms [50]. Even-though these mechanisms do
not replace the loss in human capital, the mechanisms
can mitigate losses through: 1) support of local foreign
scientists, 2) establishment of equal partnerships in col-
laborative efforts between foreign-born scientists resid-
ing in industrialized countries with leaders and scientists
of their countries of origins, 3) specific targeted compensa-
tion to build genomics/biomedical/health infrastructure,
and 4) technology transfer among public and private sec-
tors, which have been shown to be successful in many
countries [86]. Within this framework, a balance will be
needed for providing incentives for individuals to return to
their country of origin versus training scientists and devel-
oping infrastructure. We must also acknowledge that cor-
ruptions and/or mismanagement of these well-intentioned
programs can perturb any advances; however, a multi-
faceted approach would be important to overcome the bar-
riers expressed in the first challenge. We advocate a
multitiered approach because it has been shown to have
success in South and Central America and in Asia [13,15].
The multitiered approach allows for investment in several
areas while also balancing competing interests. The situ-
ation in SSA is quite challenging; nonetheless, if the rec-
ommendations are implemented within SSA success is
also possible [13,18,87].
Overall a positive perception of research conducted by
African scientists in SSA is gaining momentum, but it
will take several years for this new paradigm to be the
norm by which research occurs in Africa. The aforemen-
tioned challenges are not exhaustive but are significant
barriers to development of biomedical technologies. A
significant need to establish and implement ethical guide-
lines that allow international researchers conducting re-
search in Africa to create capacity and also to help train
the next generation of African scientists should be
addressed. These issues are not only for the international
community but also for African scientists who have sig-
nificant obligations to develop the research infrastructure
and culture within their own countries. For example, sev-
eral areas that could be addressed without significant
international coordination include collaboration amongst
African scientists in Africa. African scientists could in-
crease collaborations in areas of training, education and
research which in turn will increase synergies in biomed-
ical and genomic research producing a lower cost for
everyone involved. These among other factors presentunique opportunities for developing biomedical research
emphasizing genomics within Africa.
Conclusion
The challenges and potential to address the health issues
of African populations are not unique to SSA because
many countries (e.g. India, Mexico, Brazil and China) have
used the development of biomedical research technologies
including genomics to begin addressing the health issues
of their respective populations [2,13]. In SSA, the Republic
of South Africa has embraced many of the tenants of
globalization including supporting the developing biotech-
nology sector [87]. In theory using biomedical research to
develop scientific capacity in Africa could significantly re-
duce the migration of intellect from low- to high-income
countries. Development of biomedical research including
genomics research in Africa could provide networking
opportunities for African research scientists, clinicians,
social scientists and bioethicists. Similarly, networking by
African scientists from different fields was instrumental
in the foundation of several research consortia (e.g.
MalariaGEN, and HapMap). This collaborative spirit
has also sponsored African students (potential research
leaders) and African scientists from the Diaspora to attend
annual meetings in Africa [88,89]. Such African Diaspora
participation generates collaborations with local African
scientists working in Africa that could ultimately mitigate
brain drain by fostering interaction [90]. The issue of brain
drain cannot be solved without budgetary commitment
from SSA countries which stand to significantly benefit
from the reduction in migration from SSA to high income
countries.
With the budgetary constraints of many low- to middle-
income African economies, committing funds to support
biomedical- and genomics-related research might be
viewed by some as an esoteric exercise. The immediate
needs for medications to prevent infectious and non-
infectious diseases in many regions of Africa are para-
mount but should not obscure the future health needs of
the population. We argue that in addition to addressing
the health needs of the population in the present, a vision
for the future is also needed. This vision should include
addressing the growing burden of NCDs while also rec-
ognizing the need to develop policies which promote
economic development through science and biotechnol-
ogy development. The needs of the populations in SSA
can be addressed while contemporaneously building a fu-
ture based on intellectual investment in people using
models from other countries. The research needs for fu-
ture populations start in the present in which biomedical
research, including genomics could be indispensable.
In terms of economics, biomedical research (such as
genomics) offers ways to foster home grown develop-
ment, manufacturing, and diagnosis and also inform on
Peprah and Wonkam Globalization and Health 2013, 9:50 Page 8 of 10
http://www.globalizationandhealth.com/content/9/1/50the delivery of healthcare. There is a tremendous oppor-
tunity for biomedical research to flourish in Africa based
on examples by many South/South collaborations; fur-
thermore, strong government commitment must be
made for the promise of biomedical research to be deliv-
ered to the African continent.
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